Reinforcement learning for context-dependent control of emergency outbreaks o...EuFMD
The 2018 Open Session of the EuFMD Standing Technical Committee was held in Borgo Egnazia - Italy, 29-31 October 2018 . The session theme was on global vaccine security
The European Commission for the Control of Foot-and-Mouth Disease (EuFMD), one of FAO’s oldest Commissions, came into being on the 12th June 1954, with the pledge of the sixth founding member state to the principles of a coordinated and common action against Foot-and-mouth Disease.
Tero-Pekka Alastalo - Blueprint Genetics - Stanford Engineering - Jan 4 2016Burton Lee
Talk by Tero-Pekka Alastalo, CEO - Blueprint Genetics (FI), at Stanford on Jan 4 2016, in our session on 'European Startup Bridges in Silicon Valley'.
Website: http://www.StanfordEuropreneurs.org
YouTube Channel: https://www.youtube.com/user/StanfordEuropreneurs
Twitter: @Europreneurs
Scientific Comprehension of Cell Line Development Strategy Based on the CHOZN...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3kO8Yku
Stable outcomes in cell line development rely heavily on the optimization of process factors in the initiation phase. This webinar will help give you an understanding of the scientific background of these factors so you can develop a flexible strategy that is appropriate for your environment.
Stable cell line development (CLD) for recombinant glycan proteins – despite its 40-year history - still suffers due to unexpected and vulnerable outputs caused by the influence of unpredictable traits of the base host cell line. However, recently - through the CHOZN-GS system - we observe better CLD performance than other CHO systems in terms of time, cost, titer, stability, and scale-up, due in part to its robust genetic stability. In particular, we find that optimization of key CLD process factors at an early stage have a large impact on the final outcome. In this talk, we will share how CLD strategies can be flexibly optimized under given conditions through an understanding of the scientific context.
In this webinar, you will learn:
• Screening & selection strategy of "easy to express Fc-fusion protein" structure
• Optimization strategy of major CLD process factor
Presented by: Dr. Young Min Oh
Senior Director, GI Innovation
Reinforcement learning for context-dependent control of emergency outbreaks o...EuFMD
The 2018 Open Session of the EuFMD Standing Technical Committee was held in Borgo Egnazia - Italy, 29-31 October 2018 . The session theme was on global vaccine security
The European Commission for the Control of Foot-and-Mouth Disease (EuFMD), one of FAO’s oldest Commissions, came into being on the 12th June 1954, with the pledge of the sixth founding member state to the principles of a coordinated and common action against Foot-and-mouth Disease.
Tero-Pekka Alastalo - Blueprint Genetics - Stanford Engineering - Jan 4 2016Burton Lee
Talk by Tero-Pekka Alastalo, CEO - Blueprint Genetics (FI), at Stanford on Jan 4 2016, in our session on 'European Startup Bridges in Silicon Valley'.
Website: http://www.StanfordEuropreneurs.org
YouTube Channel: https://www.youtube.com/user/StanfordEuropreneurs
Twitter: @Europreneurs
Scientific Comprehension of Cell Line Development Strategy Based on the CHOZN...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3kO8Yku
Stable outcomes in cell line development rely heavily on the optimization of process factors in the initiation phase. This webinar will help give you an understanding of the scientific background of these factors so you can develop a flexible strategy that is appropriate for your environment.
Stable cell line development (CLD) for recombinant glycan proteins – despite its 40-year history - still suffers due to unexpected and vulnerable outputs caused by the influence of unpredictable traits of the base host cell line. However, recently - through the CHOZN-GS system - we observe better CLD performance than other CHO systems in terms of time, cost, titer, stability, and scale-up, due in part to its robust genetic stability. In particular, we find that optimization of key CLD process factors at an early stage have a large impact on the final outcome. In this talk, we will share how CLD strategies can be flexibly optimized under given conditions through an understanding of the scientific context.
In this webinar, you will learn:
• Screening & selection strategy of "easy to express Fc-fusion protein" structure
• Optimization strategy of major CLD process factor
Presented by: Dr. Young Min Oh
Senior Director, GI Innovation
Advancing Innovation and Convergence in Cancer Research: US Federal Cancer Mo...Jerry Lee
Special Seminar at the 8th Taiwan Biosignatures Workshop to share overall work of NCI's Center for Strategic Scientific Initiatives since 2003 as well as CSSI's influence on select projects initiated by the 2016 WH Cancer Moonshot Task Force that include Applied Proteogenomics Organizational Learning and Outcomes (APOLLO) network, International Cancer Proteogenome Consortium, and the Blood Profiling Atlas in Cancer (BloodPAC) commons.
Bladder Cancer Diagnostic-Initial Team ProjectSagar Desai
A mini-project to find biomarkers for bladder cancer diagnosis. We narrowed down our list of viable candidates down to three that could be used in combination to provide sensitivity and specificity values greater than 94%. Furthermore, we calculated long-term monitoring and payor costs as well as potential profit.
Steve Rozen's keynote talk at IEEE CIBCB 2016
Big Genome Data Sheds Light on Cancer Causes
Steven G. Rozen, PhD
Professor, Cancer & Stem Cell Programme, Duke-NUS Medical School, Singapore
Director, Duke-NUS Centre for Computational Biology
The last eight years have see a revolution in the availability of DNA sequencing data. This revolution has been driven by costs that have plummeted from US$ 10 million per human genome in 2008 to US $1,200 today. Abundant sequencing data brings with it a previously unimaginable range of research possibilities in all areas of biomedical research. Naturally, these research possibilities make heavy demands on computation and data storage, because costs of sequencing are falling much faster than Moore's law. In this talk I will present a high level overview of these computational demands. I will then go into detail on a few of the cancer-related big data projects my lab is working on. One of these is "mutation signature analysis", which has important applications in cancer prevention and epidemiology and in research into the fundamental processes by which cancers arise. One example of the importance of this approach is the recent finding that a highly mutagenic herbal remedy is implicated in many more geographical regions and types of cancer than suspected a few years ago.
Advancing Innovation and Convergence in Cancer Research: US Federal Cancer Mo...Jerry Lee
Special Seminar at the 8th Taiwan Biosignatures Workshop to share overall work of NCI's Center for Strategic Scientific Initiatives since 2003 as well as CSSI's influence on select projects initiated by the 2016 WH Cancer Moonshot Task Force that include Applied Proteogenomics Organizational Learning and Outcomes (APOLLO) network, International Cancer Proteogenome Consortium, and the Blood Profiling Atlas in Cancer (BloodPAC) commons.
Bladder Cancer Diagnostic-Initial Team ProjectSagar Desai
A mini-project to find biomarkers for bladder cancer diagnosis. We narrowed down our list of viable candidates down to three that could be used in combination to provide sensitivity and specificity values greater than 94%. Furthermore, we calculated long-term monitoring and payor costs as well as potential profit.
Steve Rozen's keynote talk at IEEE CIBCB 2016
Big Genome Data Sheds Light on Cancer Causes
Steven G. Rozen, PhD
Professor, Cancer & Stem Cell Programme, Duke-NUS Medical School, Singapore
Director, Duke-NUS Centre for Computational Biology
The last eight years have see a revolution in the availability of DNA sequencing data. This revolution has been driven by costs that have plummeted from US$ 10 million per human genome in 2008 to US $1,200 today. Abundant sequencing data brings with it a previously unimaginable range of research possibilities in all areas of biomedical research. Naturally, these research possibilities make heavy demands on computation and data storage, because costs of sequencing are falling much faster than Moore's law. In this talk I will present a high level overview of these computational demands. I will then go into detail on a few of the cancer-related big data projects my lab is working on. One of these is "mutation signature analysis", which has important applications in cancer prevention and epidemiology and in research into the fundamental processes by which cancers arise. One example of the importance of this approach is the recent finding that a highly mutagenic herbal remedy is implicated in many more geographical regions and types of cancer than suspected a few years ago.
Basem AL Al Zahrany
How effective is CT Colonography in detecting colon cancer?
Introduction
The second cause leading to death in the United States is colorectal cancer in the same way colorectal cancer is the third common cancer in women and men. In the United States 135,260 people diagnosed with colorectal cancer in 2011. Colorectal cancer caused for 51,783 people from them the death. The number of colorectal cancer patients is predictable to rise in the future. Built on the present data, cost scenario and survival for colorectal cancer Yabroff et al expected the cost effect in 2020 for the primary $4.05 billion, making a significant cost load on the healthcare system. Colorectal cancer mortality was decreased by 18% to13 % with apply CT Colonography to detect colonic polyps before they developed to colorectal cancer (Trilisky et al, 2015). CT Colonography has been shown to have polyp discovery rates similar to the patient how use colonoscopy. CT Colonography is an exam for colorectal cancer screening which became generally effected for detecting polyps similar to those of colonoscopy. It has the prospective to improve colorectal cancer screening rates because of colorectal is come to be insignificant noninvasive ,faster patient in quantity ,no sedation requirement and potential for reduced cathartic examination . Appropriate program of a CT Colonography screening must implement and needs important announce to several aspects, counting proper patient preparation before the investigation, image acquisition, and post-processing of the developed images. A CT Colonography need workstation with special software and high quality monitors. Special software called Computer-Aided Detection CAD which is manipulate to reduce mistakes of spotting and showing polyps to the radiologist for images interpretation. These essay will discuss technique, advantages , disadvantages of CT Colonography and how CT Colonography can be affect for colorectal cancer .
Exam technique
Currently, patients go through intestine preparation procedure which has the purpose of avoid misdiagnosed of polyps by cleaning the colon. So far there is no agreement on a best program of food adjustment and releasing preparation of flexible period and amount. There is continuing studies aimed to rise patient relaxation and acceptance. To distinguish polyps from other residual the use usually fecal and fluid tagging with bowel laxative. Some time they do it with small quantity of both iodine-based contrast material and barium or one of them to improve the image and to eliminate the artifact of image which could be accrue ,which may rise the sensitivity of polyp detection, Digital subtraction is a post-acquisition processing technique use to improve the image quality(Trilisky,2015).
Advantages of CT Colonography
CT Colonography shows high sensitivit ...
Development of a new venture pioneering medical screening tests for a number of diseases simply though breath samples. This technology is changing the way people check on their health and will save millions of lives through the early detection of Lung cancer alone.
Advancing Convergence and Innovation in Cancer ResearchJerry Lee
Describes NCI's Center for Strategic Scientific Initiatives activities (2005 - 2017) as well as data and technology activities of the 2016 White House Cancer Moonshot Task Force (2016 - 2017).
Keys of Success in Research: Tanta University, Egypt as a Case study
Center of Excellence in Cancer Research
Grants, Innovation & Technology Transfer Center
WCRF International Continuous Update Project (CUP). Presentation given by Giota Mitrou PhD MSc, Head of Research Funding and Science Activities, World Cancer Research Fund International (WCRF International).
Morphologomics - Challenges for Surgical Pathology in the Genomic Age by Dr. ...Cirdan
This presentation introduces and discussesthe concept of ‘morphologomics’ that is omics approaches critically reimagined and reappraised from the viewpoint of classic morphology.
It was delivered by Dr. Anthony Gill at the Pathology Horizons 2017 conference in Cairns, Australia.
introduce and discuss the concept of ‘morphologomics’ that is omics approaches critically reimagined and reappraised from the viewpoint of classic morphology.
(December 2, 2021) The Bench to Bedside Series: Preclinical Cancer Research w...Scintica Instrumentation
Overview:
The goal of this webinar will be to provide a high-level overview of the various stages of preclinical cancer research and discuss the role that innovative instrumentation can play in moving science forward.
To better understand how to treat and control cancer, researchers start by investigating the basics – the cells, molecules, and genes that make up the human body. This type of study, which is often referred to as basic or discovery research, aims to understand the underlying mechanisms contributing to cancer growth and spread. This knowledge is an essential starting point for developing future diagnostic tests and treatment strategies.
After finding an innovative idea that works in cells, researchers need to take their studies to the next level by employing animal models that have similar biology to humans. Animal models have helped scientists make some of the most important cancer discoveries over the years. Furthermore, preclinical imaging technologies allow researchers to perform longitudinal animal studies that are noninvasive leaving the underlying biology intact so that one can track changes throughout the entire disease process.
It was previously thought that the journey from bench to bedside was unidirectional, starting with discovery research and moving towards clinical trials. However, in the last decade, it has become crucial for basic scientists and clinicians to work together towards finding innovative solutions that will positively impact patient care.
After attending this webinar, we hope you will have a better understanding of the preclinical workflow needed to push an idea from bench to bedside as well as some of the key equipment that is needed along the way.
This webinar series will be hosted by Drs. Katie Parkins and Tyler Lalonde, both of which have extensive experience in translational research areas including oncology, neuroscience, molecular imaging, and drug development.
In this webinar we will discuss the following topics:
• Introduction To Cancer Research
• What does “Bench to Bedside” mean?
• In vitro characterization
• Rapid throughput screening
• Quantitative tools
• Moving towards translation
Similar to Canary Foundation Luncheon - March 26, 2105 (20)
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
8. 1p
IT
F01
IN
d
dt
q1p = (IN + IT)-q1p x F01
IN + IT
(1-e-F01t)q1p =
F01
ln(2)
t1/2marker
qsts=
[IN(mass/time) + IT(mass/time)]
Steady state can be calculated as:
# 2 Cancer generates measurable items in blood
9. # 3 But old technology can’t find it until too large
10. # 4 New nano-technology can find it 1000 times
smaller and 1000 times cheaper!
21. Scientific Panel
Sanjiv Sam Gambhir, MD, PhD – Chair, Department of Radiology,
Stanford University
Jim Brooks, MD - Chief, Urologic Oncology, Stanford University
Utkan Demirci, PhD - Associate Professor, Stanford University
Heidi Auman, PhD – Scientific Program Manager,
Canary Foundation
34. Development of a Clinical Test Clinical Trials for CT + Biomarkers
CT + Biomarker Trial
initiated by MD Anderson
10,000 in US &
International
participation in China,
Germany, Brazil
Multiple techniques to analyze a
common set of samples
Integrate data and discover biomarkers
Smokers vs. Never Smokers
Cell Lines Tumors Blood
Pro-Surfactant Protein B (pro-SFTPB)
Validation
Lung cancer research & clinical trial
39. PASS Clinical Trial
1,000+ Men
5 Year
Follow-upNo Progression
Suspected
Central
Bio-Repository
Progression Suspected
Option for Treatment
Tissue Resources for Validation
Tissue of 1,000+
men who have
had radical
treatment
500+ Non-recurrent cancer
500+ Recurrent cancer
1,000s of prostate cancer
tissues arrayed to maximize
rapid and efficient analysis
Prostate cancer clinical trial
50. Clinical Trials
Prostate Ovary Pancreas
$1,500 to sponsor 1 person
$3,000 to sponsor 2 people
$4,500 to sponsor 3 people
51.
52. Thank You
Canary Luncheon Committee
Dear Pixels
Lobird
Laure Woods
Avaya
Union Bank
Village Doctors
William K Bowes Jr. Foundation
Franklin and Cathryn Johnson Family Foundation
Debbi Spungen in memory of Florence Spungen